PL3850113T3 - Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów - Google Patents

Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów

Info

Publication number
PL3850113T3
PL3850113T3 PL19762829.0T PL19762829T PL3850113T3 PL 3850113 T3 PL3850113 T3 PL 3850113T3 PL 19762829 T PL19762829 T PL 19762829T PL 3850113 T3 PL3850113 T3 PL 3850113T3
Authority
PL
Poland
Prior art keywords
ostearthritis
treatment
markers useful
enrichment strategies
enrichment
Prior art date
Application number
PL19762829.0T
Other languages
English (en)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine BAY-JENSEN
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL3850113T3 publication Critical patent/PL3850113T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
PL19762829.0T 2018-09-10 2019-09-09 Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów PL3850113T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18193351 2018-09-10
PCT/EP2019/074003 WO2020053155A1 (en) 2018-09-10 2019-09-09 Markers useful in enrichment strategies for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
PL3850113T3 true PL3850113T3 (pl) 2024-09-02

Family

ID=63685561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19762829.0T PL3850113T3 (pl) 2018-09-10 2019-09-09 Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów

Country Status (18)

Country Link
US (2) US12383603B2 (pl)
EP (1) EP3850113B1 (pl)
JP (2) JP7568614B2 (pl)
KR (1) KR20210057764A (pl)
CN (1) CN113286896A (pl)
AU (1) AU2019337786B2 (pl)
BR (1) BR112021004356A2 (pl)
CA (1) CA3111671A1 (pl)
DK (1) DK3850113T3 (pl)
ES (1) ES2980597T3 (pl)
FI (1) FI3850113T3 (pl)
HR (1) HRP20240665T1 (pl)
HU (1) HUE067058T2 (pl)
IL (1) IL281333B2 (pl)
MX (1) MX2021002803A (pl)
PL (1) PL3850113T3 (pl)
SG (1) SG11202102160VA (pl)
WO (1) WO2020053155A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
GB2630642A (en) * 2023-06-02 2024-12-04 Mako Surgical Corp Image processing method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837841A (en) 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US8207115B2 (en) 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) * 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
UA130140C2 (uk) * 2018-02-14 2025-11-26 Долбі Лабораторіс Лайсензін Корпорейшн Перетворення зображення в кодуванні відео з використанням оптимізації залежності викривлення від швидкості передачі
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
EP3850113A1 (en) 2021-07-21
CA3111671A1 (en) 2020-03-19
JP2022511305A (ja) 2022-01-31
IL281333A (en) 2021-04-29
KR20210057764A (ko) 2021-05-21
AU2019337786A1 (en) 2021-04-15
EP3850113B1 (en) 2024-04-03
HUE067058T2 (hu) 2024-09-28
US20260102469A1 (en) 2026-04-16
US12383603B2 (en) 2025-08-12
IL281333B1 (en) 2025-07-01
AU2019337786B2 (en) 2026-02-05
IL281333B2 (en) 2025-11-01
WO2020053155A1 (en) 2020-03-19
FI3850113T3 (fi) 2024-07-03
US20220047674A1 (en) 2022-02-17
DK3850113T3 (da) 2024-06-10
CN113286896A (zh) 2021-08-20
JP2025000980A (ja) 2025-01-07
JP7568614B2 (ja) 2024-10-16
MX2021002803A (es) 2021-07-16
ES2980597T3 (es) 2024-10-02
HRP20240665T1 (hr) 2024-08-16
SG11202102160VA (en) 2021-04-29
BR112021004356A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
IL280536A (en) Muscle targeting complexes and uses thereof
IL279965A (en) Fusion constructs and methods of using thereof
IL282998A (en) Pyridazinone compounds and uses thereof
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
MA45192A (fr) Traitement d'association
IL278122B1 (en) Pteridinone compounds and uses thereof
EP3497086A4 (en) AMINOPYRIMIDINE SSAO INHIBITORS
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
IL248299B (en) A method and kit for determining the tissue or cell origin of dna
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3429571T3 (da) Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA49006A (fr) Inhibiteurs d'ip6k
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
HUE067058T2 (hu) Oszteoartritisz kezelésére szolgáló dúsítási stratégiákban alkalmazható markerek
DK3532059T3 (da) Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego